Adicet Bio, Inc. (NASDAQ:ACET – Get Free Report) has earned a consensus recommendation of “Moderate Buy” from the seven research firms that are covering the stock, MarketBeat.com reports. Three investment analysts have rated the stock with a hold recommendation and four have issued a buy recommendation on the company. The average 12-month price objective among […]
Adicet Bio, Inc. , a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for autoimmune diseases and cancer, today announced it granted an.
Adicet Bio (NASDAQ:ACET) Upgraded to Sell by StockNews com theenterpriseleader.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from theenterpriseleader.com Daily Mail and Mail on Sunday newspapers.